82924
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 7
- e1_e2
- E1
- umap1_2d
- -3.774320052
- umap2_2d
- 1.334448271
- umap1_3d
- 0.303508588
- umap2_3d
- 3.63914461
- umap3_3d
- -0.889174683
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.460
- INTERFERON_GAMMA_RESPONSE+0.430
- E2F_TARGETS+0.300
- PROTEIN_SECRETION+0.290
- G2M_CHECKPOINT+0.280
- IL6_JAK_STAT3_SIGNALING+0.250
- MITOTIC_SPINDLE+0.240
- COMPLEMENT+0.230
- KRAS_SIGNALING_UP+0.220
- ANDROGEN_RESPONSE+0.210
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.410
- UV_RESPONSE_UP-0.280
- APICAL_SURFACE-0.270
- MYOGENESIS-0.250
- ANGIOGENESIS-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.240
- KRAS_SIGNALING_DN-0.190
- MYC_TARGETS_V2-0.190
- HEDGEHOG_SIGNALING-0.180
- PANCREAS_BETA_CELLS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 90c9f8cd-4c8c-4f07-af2f-e17db69bd561 | — | — | 0.780 |
| 2 | TCGA-44-2656-01A-02R-A278-07 | — | cohortMD2 | 0.777 |
| 3 | SRR8518384 | — | D | 0.776 |
| 4 | TCGA-E9-A248-01A-11R-A169-07 | — | C | 0.767 |
| 5 | aefb974b-c7d9-47f0-8f18-9346c087ea64 | — | — | 0.757 |
| 6 | 06d5607b-45d7-4247-8d42-709d9d292530 | — | — | 0.756 |
| 7 | TCGA-D8-A1JG-01B-11R-A13Q-07 | — | C | 0.753 |
| 8 | MNG1225 | — | — | 0.745 |
| 9 | TCGA-55-7994-01A-11R-2187-07 | — | cohortA1 | 0.743 |
| 10 | C3N-02234 | — | cohortA1 | 0.727 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |